Pediatric pneumococcal vaccine

The vaccines available today defend against many types (strains) of pneumococcal bacteria, but they don’t protect against all. That’s why we are researching if an investigational formulation of our pneumococcal vaccine can help protect against more strains.

Get Your Patient FormDownload Brochure
804-477-3045
Get Your Patient Form
Summary
  • Your child will receive 1 dose of the study vaccine or a licensed pneumococcal vaccine called Prevnar 20®.
  • Participation lasts about 6 months.
  • There is no cost to participate.
  • Taking part in this clinical trial may help improve vaccine protection not only for your child, but also other children in the future.
 
Qualifications
This study is enrolling healthy children and teens who:
  • Are 15 to 23 months old and have received at least 2 prior doses of a pneumococcal vaccine, OR
  • Are 2 to 17 years old and have received 0 to 4 prior doses of a pneumococcal vaccine

Meet Our Team

Our experienced team will guide you through the process

Meet the Team

Dr. Call, co-founder of Clinical Research Partners, serves as President. He is a Certified Principle Investigator

Robert S. Call, MD, CPI

President

Annette Bennett, co-founder of Clinical Research Partners, serves as Chief Executive Officer and Research Director. She

Annette Bennett

Chief Executive Officer

Bo Vaughan is a native of Richmond, VA and forward-thinking health care strategist with a

Bo Vaughan, MD, MSHA, CPI

Medical Director

Mimi Franzen Canada

Chief Operations Officer

Jeanette Weller

EVP of Contracts and Budgets

Caitlin Vining

Controller CCRP

Kelly Craighead, BS, RN, CCRC

Regulatory Affairs Director

Carly McLaughlin, PharmD

Director of Pharmacy PharmD

Lisa Smith, BSN, RN

Director of Quality Assurance

Joy Walker

Director of Business Development

Aundraya Bray, LCSW

Clinical Operations Coordinator

Shawn Mease, CCRC, NRP, CCEMT-P

Director of Study Start-Up